Article info

other Versions

PDF

Extended report
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

Authors

  1. Correspondence to Dr Primal Kaur, Biosimilars Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; pkaur{at}amgen.com
View Full Text

Citation

Kaur P, Chow V, Zhang N, et al
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

Publication history

  • Received November 17, 2015
  • Revised June 28, 2016
  • Accepted June 29, 2016
  • First published July 27, 2016.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.